118 related articles for article (PubMed ID: 22503900)
1. Combination of p53(ser15) and p21/p21(thr145) in peripheral blood lymphocytes as potential Alzheimer's disease biomarkers.
Tan M; Wang S; Song J; Jia J
Neurosci Lett; 2012 May; 516(2):226-31. PubMed ID: 22503900
[TBL] [Abstract][Full Text] [Related]
2. G1/S checkpoint proteins in peripheral blood lymphocytes are potentially diagnostic biomarkers for Alzheimer's disease.
Song J; Wang S; Tan M; Jia J
Neurosci Lett; 2012 Sep; 526(2):144-9. PubMed ID: 22922216
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial fission proteins in peripheral blood lymphocytes are potential biomarkers for Alzheimer's disease.
Wang S; Song J; Tan M; Albers KM; Jia J
Eur J Neurol; 2012 Jul; 19(7):1015-22. PubMed ID: 22340708
[TBL] [Abstract][Full Text] [Related]
4. Decreased plasma levels of soluble low density lipoprotein receptor-related protein-1 (sLRP) and the soluble form of the receptor for advanced glycation end products (sRAGE) in the clinical diagnosis of Alzheimer's disease.
Liang F; Jia J; Wang S; Qin W; Liu G
J Clin Neurosci; 2013 Mar; 20(3):357-61. PubMed ID: 23228658
[TBL] [Abstract][Full Text] [Related]
5. P53-mediated G(1)/S checkpoint dysfunction in lymphocytes from Alzheimer's disease patients.
Zhou X; Jia J
Neurosci Lett; 2010 Jan; 468(3):320-5. PubMed ID: 19914341
[TBL] [Abstract][Full Text] [Related]
6. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
[TBL] [Abstract][Full Text] [Related]
7. Combination of plasma biomarkers and clinical data for the detection of sporadic Alzheimer's disease.
Han Y; Jia J; Jia XF; Qin W; Wang S
Neurosci Lett; 2012 May; 516(2):232-6. PubMed ID: 22503901
[TBL] [Abstract][Full Text] [Related]
8. Conformationally altered p53: a novel Alzheimer's disease marker?
Lanni C; Racchi M; Mazzini G; Ranzenigo A; Polotti R; Sinforiani E; Olivari L; Barcikowska M; Styczynska M; Kuznicki J; Szybinska A; Govoni S; Memo M; Uberti D
Mol Psychiatry; 2008 Jun; 13(6):641-7. PubMed ID: 17684496
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid markers in differential diagnosis of Alzheimer's disease and vascular dementia.
Boban M; Grbić K; Mladinov M; Hof PR; Süssmair C; Ackl N; Stanić G; Bader B; Danek A; Simić G
Coll Antropol; 2008 Jan; 32 Suppl 1():31-6. PubMed ID: 18405055
[TBL] [Abstract][Full Text] [Related]
10. Conformationally altered p53: a putative peripheral marker for Alzheimer's disease.
Uberti D; Lanni C; Racchi M; Govoni S; Memo M
Neurodegener Dis; 2008; 5(3-4):209-11. PubMed ID: 18322392
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population.
Johansson P; Mattsson N; Hansson O; Wallin A; Johansson JO; Andreasson U; Zetterberg H; Blennow K; Svensson J
J Alzheimers Dis; 2011; 24(3):537-46. PubMed ID: 21297262
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma.
Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
J Urol; 2007 Feb; 177(2):481-7; discussion 487. PubMed ID: 17222615
[TBL] [Abstract][Full Text] [Related]
13. Unfolded p53 in blood as a predictive signature signature of the transition from mild cognitive impairment to Alzheimer's disease.
Lanni C; Racchi M; Stanga S; Mazzini G; Ranzenigo A; Polotti R; Memo M; Govoni S; Uberti D
J Alzheimers Dis; 2010; 20(1):97-104. PubMed ID: 20164600
[TBL] [Abstract][Full Text] [Related]
14. CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease.
Chiasserini D; Parnetti L; Andreasson U; Zetterberg H; Giannandrea D; Calabresi P; Blennow K
J Alzheimers Dis; 2010; 22(4):1281-8. PubMed ID: 20930282
[TBL] [Abstract][Full Text] [Related]
15. Exploring the value of plasma BIN1 as a potential biomarker for alzheimer's disease.
Sun L; Tan MS; Hu N; Yu JT; Tan L
J Alzheimers Dis; 2013; 37(2):291-5. PubMed ID: 23803295
[TBL] [Abstract][Full Text] [Related]
16. A single recombinant adenovirus expressing p53 and p21-targeting artificial microRNAs efficiently induces apoptosis in human cancer cells.
Idogawa M; Sasaki Y; Suzuki H; Mita H; Imai K; Shinomura Y; Tokino T
Clin Cancer Res; 2009 Jun; 15(11):3725-32. PubMed ID: 19458054
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer's disease.
Formichi P; Battisti C; Radi E; Federico A
J Cell Physiol; 2006 Jul; 208(1):39-46. PubMed ID: 16447254
[TBL] [Abstract][Full Text] [Related]
18. Increased alpha 7 nicotinic acetylcholine receptor protein levels in Alzheimer's disease patients.
Chu LW; Ma ES; Lam KK; Chan MF; Lee DH
Dement Geriatr Cogn Disord; 2005; 19(2-3):106-12. PubMed ID: 15591800
[TBL] [Abstract][Full Text] [Related]
19. Peripheral expression of MAPK pathways in Alzheimer's and Parkinson's diseases.
Wang S; Zhang C; Sheng X; Zhang X; Wang B; Zhang G
J Clin Neurosci; 2014 May; 21(5):810-4. PubMed ID: 24405770
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.
Ibach B; Binder H; Dragon M; Poljansky S; Haen E; Schmitz E; Koch H; Putzhammer A; Kluenemann H; Wieland W; Hajak G
Neurobiol Aging; 2006 Sep; 27(9):1202-11. PubMed ID: 16085339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
